Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioblastoma × vandetanib × Clear all

Phase

Phase 1 3 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Carcinoma, Medullary 3 Thyroid Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Endocrine Neoplasia Type 2b 1 Multiple Endocrine Neoplasia Type 2a 1 Multiple Endocrine Neoplasia 1 Gliosarcoma 1 Glioblastoma 1 Carcinoma, Renal Cell 1

Interventions

Temozolomide 65 Radiotherapy 26 Bevacizumab 23 Carboplatin 12 Radiation 11 pembrolizumab 10 Irinotecan 7 Carmustine 7 Surgical Procedures, Operative 6 Radiosurgery 6 Erlotinib Hydrochloride 6 Nivolumab 5 Everolimus 5 temsirolimus 4 atezolizumab 4 Vorinostat 4 Radiotherapy, Intensity-Modulated 4 Lomustine 4 Aminolevulinic Acid 4 tipifarnib 3 fludarabine 3 Sirolimus 3 Radiotherapy, Conformal 3 Paclitaxel 3 Magnetic Resonance Spectroscopy 3 IL13-PE38 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Gemcitabine 3 Drug Therapy 3 Cyclophosphamide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00441142 2019-03-05

Zactima

Dana-Farber Cancer Institute

Phase 1/2 Completed

119 enrolled 15 charts

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡